Halozyme Wins Preliminary Injunction Against Merck’s Keytruda SC in Germany

Halozyme Therapeutics, Inc. has achieved a significant legal victory in Germany by obtaining a preliminary injunction against Merck’s subcutaneous version of Keytruda (Keytruda SC). This court order prohibits Merck from selling Keytruda SC in Germany during the ongoing patent dispute.

Background of the Dispute

Halozyme filed the injunction on grounds that Keytruda SC infringes on its patented drug delivery technology. This technology uses a proprietary enzyme that enhances the absorption and effectiveness of injected drugs, a key element in Keytruda SC’s design.

Key Points of the Court Decision

• The injunction was granted following a detailed examination of patent claims related to Halozyme’s enzyme technology.
• The ruling serves as an early measure to prevent potential harm from patent infringement while the case proceeds.
• Merck’s subcutaneous Keytruda offers patients a more convenient administration method compared to intravenous injections.

Implications

1. The injunction may delay the availability of Keytruda SC in Germany, affecting market dynamics and patient treatment options.
2. Halozyme maintains control over its patented technology in the German market.
3. Merck has yet to respond publicly or indicate if it will appeal the court’s decision.

Industry Impact

This case underscores the critical role of innovations in drug delivery and the importance of patent protection in the pharmaceutical sector. The dispute illustrates the competitive nature of advancements aimed at improving cancer treatment.

The final resolution is expected after a full trial scheduled for later this year. Meanwhile, the injunction restricts Keytruda SC’s sale and distribution in Germany.

About The Author